Evidence map›Paper›PMID 41146443›Full record

Trial reportBiometrical journal. Biometrische Zeitschrift2025

Variable Selection via Fused Sparse-Group Lasso Penalized Multi-state Models Incorporating Molecular Data.

Kaya Miah, Jelle J Goeman, Hein Putter, Annette Kopp-Schneider, Axel Benner

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Biometrical journal. Biometrische Zeitschrift, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00893399 (Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00893399 phase3completednot on this map

Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation

TypeinterventionalSponsorUniversity of UlmRan2010 to 2021Enrolled600ConditionsAcute Myeloid LeukemiaArmsGemtuzumab Ozogamicin (Mylotarg), standard chemotherapy
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kaya MiahDivision of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-0265-3529
Jelle J GoemanDepartment of Biomedical Data Sciences, Leiden University Medical Center (LUMC), Leiden, The Netherlands.ORCID 0000-0003-4283-0259
Hein PutterDepartment of Biomedical Data Sciences, Leiden University Medical Center (LUMC), Leiden, The Netherlands.ORCID 0000-0001-5395-1422
Annette Kopp-SchneiderDivision of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-1810-0267
Axel BennerDivision of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-7238-6956

Funding

Deutsche Forschungsgemeinschaft 514653984
6 · The paper itself

Abstract

In multi-state models based on high-dimensional data, effective modeling strategies are required to determine an optimal, ideally parsimonious model. In particular, linking covariate effects across transitions is needed to conduct joint variable selection. A useful technique to reduce model complexity is to address homogeneous covariate effects for distinct transitions. We integrate this approach to data-driven variable selection by extended regularization methods within multi-state model building. We propose the fused sparse-group lasso (FSGL) penalized Cox-type regression in the framework of multi-state models combining the penalization concepts of pairwise differences of covariate effects along with transition-wise grouping. For optimization, we adapt the alternating direction method of multipliers (ADMM) algorithm to transition-specific hazards regression in the multi-state setting. In a simulation study and application to acute myeloid leukemia (AML) data, we evaluate the algorithm's ability to select a sparse model incorporating relevant transition-specific effects and similar cross-transition effects. We investigate settings in which the combined penalty is beneficial compared to global lasso regularization. Clinical Trial Registration: The AMLSG 09-09 trial is registered with ClinicalTrials.gov (NCT00893399) and has been completed.

Indexed as

BiometryModels, StatisticalAlgorithmsComputer SimulationHumansLeukemia, Myeloid, AcuteProportional Hazards ModelsCox‐type regressionhigh‐dimensional dataMarkov modelsregularizationtransition‐specific hazards

Identifiers

PMID41146443
PMCPMC12559784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.